MODERATOR(S)
Brett Morris, MD, PhD - University of Wisconsin Madison
session DESCRIPTION
Tumor treating fields (TTF) have been shown to increase survival in patients with glioblastoma, lung cancer and pancreatic cancer, and time to intracranial progression in select patients with lung cancer brain metastases. Despite these impressive outcomes, many physicians have been reluctant to adopt TTF as part of their standard of care. This may be due to lack of knowledge surrounding the mechanism of action and biological consequences of TTF, distrust in the trials due to the potential conflicts of interest inherent in the trials, or simply because many practitioners lack the training and education required to provide this therapy. The goal of this session is to educate the audience about the mechanisms and phase III randomized evidence of TTF in a non-biased manner. We also aim to provide practical guidance on how to use TTF in your practice environment.
learning objectives
- Explain at least three possible biological mechanisms of Tumor Treating Fields.
- Be able to interpret TTF clinical trial data and understand the implications for their own practice.
- Understand how to practically implement TTF in their practice setting.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
08:00am - 08:02am ETSpeaker: Brett Morris, MD, PhD - University of Wisconsin Madison, Madison
-
08:02am - 08:17am ETSpeaker: Michael Story, PhD - University of Texas Southwestern Medical Center, Dallas
-
08:17am - 08:32am ETSpeaker: David Roberge, MD - Centre Hospitalier de l'Universite de Montreal, Montreal
-
08:32am - 08:47am ETSpeaker: Megan Daly, MD - University of California, Davis, Sacramento
-
08:47am - 09:00am ETSpeaker: Brett Morris, MD, PhD - University of Wisconsin Madison, Madison